Search

250 Result(s)
Sort by

GlyT1 Phase II results

GlyT1 Phase II results

Boehringer Ingelheim refocuses Gly-T1 inhibition brain research on schizophrenia
Interview: Excellence in stem cell treatments

Interview: Excellence in stem cell treatments

Acquisition of GST reflects the potential of biotechnology research. Goal is to provide breakthrough therapies for diseases in companion animals. 
Women in STEM 2022

Women in STEM 2022

Meet three of Boehringer Ingelheim's female scientists and learn why and how women are making a difference in STEM.
Innovation in medicinal chemistry

Innovation in medicinal chemistry

Darryl McConnell, Senior Vice President and Research Site Head, Austria and Jürgen Mack, Vice-President, Medicinal Chemistry, explain how we are working to unlock unsolved diseases
EHS management approach

EHS management approach

We protect our employees, facilities and the environment from harmful influences, conserve natural resources and promote environmental awareness
Empowering all employees

Empowering all employees

Boehringer Ingelheim has been awarded as a Global Top Employer for the second year in succession
Advancing regenerative medicine

Advancing regenerative medicine

Strategic partnerships play a key role in helping the company accelerate the next generation of breakthroughs.
View from Both Sides of the Table

View from Both Sides of the Table

Scott DeWire, US Head of BD&L shares experiences that have taught him first-hand the foundations of successful partnerships
International Women's Day

International Women's Day

We celebrate International Women’s Day with this year’s UN Women motto being “Gender Equality Today for a Sustainable Tomorrow”